Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
Stephen J. Shuttleworth(Karus Therapeutics (United Kingdom)), Paul Workman(Institute of Cancer Research)
Cited by 103
Related Papers
Guidelines for the welfare and use of animals in cancer research
|British Journal of Cancer|2010|1.4k
Discovery of small molecule cancer drugs: Successes, challenges and opportunities
|Molecular Oncology|2012|581
The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations
|British Journal of Cancer|2005|513
New approaches to molecular cancer therapeutics
|Nature Chemical Biology|2006|387